phase iii independence trial of luspatercept in patients with td myelofibrosis on jaki therapy
Published 2 years ago • 256 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
2:15
independence: luspatercept vs placebo in mpns-associated myelofibrosis
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
2:26
ace-536-mf-001 update: luspatercept for the treatment of anemia in myelofibrosis
-
1:40
long-term follow-up of luspatercept: response duration and progression to aml
-
3:22
jak2 inhibition in the treatment of myelofibrosis
-
7:03
jak2 v617f vaf as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
7:42
phase ii trial of bomedemstat for advanced myelofibrosis
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
5:26
nct03194542 trial: luspatercept for the treatment of patients with anemic myelofibrosis
-
2:44
trial in progress: anti-slamf7 elotuzumab in jak2-mutated myelofibrosis
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
2:06
second-line myelofibrosis treatment – the potential of jak2 inhibitor ns-018
-
1:55
the promise of pelabresib in mf and insights into the manifest-2 study
-
1:20
to jaki or not to jaki - treating early mf
-
1:25
phase ii trial of eprenetapopt plus azacitidine: long-term follow up
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
0:41
isct in bringing together the scientific community
-
1:52
investigating luspatercept utilization patterns in lower-risk mds
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll